LUNG · NASDAQ
Pulmonx (LUNG) Stock Price & Fundamentals
Pulmonx (LUNG) closed at $714.91 on Oct 9, 2026, up 0.19% from the previous close of $713.54.
Share price, past year
1Y +35.89%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $714.91 |
| Sep 30, 2026 | $708.38 |
| Aug 31, 2026 | $650.11 |
| Jul 31, 2026 | $630.01 |
| Jun 30, 2026 | $603.14 |
| May 29, 2026 | $590.19 |
| Apr 30, 2026 | $578.45 |
| Mar 31, 2026 | $608.32 |
| Feb 27, 2026 | $601.68 |
| Jan 30, 2026 | $560.79 |
| Dec 31, 2025 | $537.64 |
| Nov 28, 2025 | $505.53 |
| Oct 31, 2025 | $518.33 |
Key statistics
- Market cap
- $30.70B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.16
- Revenue (TTM)
- $87.44M
- Net income (TTM)
- −$48.12M
- Shares outstanding
- 42.9M
- Dividend yield
- —
- 52-week range
- $501.23 – $721.87
Pulmonx's market cap is $30.70B, based on a share price of $714.91 and 42.9M shares outstanding as of Jun 30, 2026.
Financials
Pulmonx reported revenue of $90.50M for fiscal 2025, up 8.01% from fiscal 2024.
Pulmonx reported a net loss of $54.00M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $90.50M | +8.0% | −$54.00M | −59.7% | −$1.33 | −$32.83M |
| FY2024ended Dec 31, 2024 | $83.79M | +22.0% | −$56.39M | −67.3% | −$1.44 | −$32.98M |
| FY2023ended Dec 31, 2023 | $68.68M | +28.0% | −$60.84M | −88.6% | −$1.60 | −$38.42M |
| FY2022ended Dec 31, 2022 | $53.66M | +10.8% | −$58.92M | −109.8% | −$1.59 | −$46.40M |
| FY2021ended Dec 31, 2021 | $48.42M | +47.9% | −$48.66M | −100.5% | −$1.35 | −$45.06M |
| FY2020ended Dec 31, 2020 | $32.73M | +0.4% | −$32.23M | −98.5% | −$3.16 | −$31.54M |
| FY2019ended Dec 31, 2019 | $32.60M | +62.9% | −$20.70M | −63.5% | −$11.66 | −$21.49M |
| FY2018ended Dec 31, 2018 | $20.00M | — | −$18.48M | −92.4% | −$11.03 | −$18.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $22.76M | −$10.08M | −$0.24 |
| Q1 FY2026ended Mar 31, 2026 | $20.59M | −$13.65M | −$0.33 |
| Q4 FY2025ended Dec 31, 2025 | $22.60M | −$10.43M | −$0.25 |
| Q3 FY2025ended Sep 30, 2025 | $21.50M | −$13.96M | −$0.34 |
| Q2 FY2025ended Jun 30, 2025 | $23.86M | −$15.17M | −$0.38 |
| Q1 FY2025ended Mar 31, 2025 | $22.54M | −$14.45M | −$0.36 |
| Q4 FY2024ended Dec 31, 2024 | $23.77M | −$13.18M | −$0.33 |
| Q3 FY2024ended Sep 30, 2024 | $20.39M | −$14.14M | −$0.36 |
Company profile
- Name
- Pulmonx Corp
- Ticker
- LUNG
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 700 Chesapeake Drive, Redwood City, CA 94063
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001127537
Recent SEC filings
- Aug 4, 2026
- Jul 29, 2026
- Jun 4, 2026
- May 4, 2026
- Apr 29, 2026
- Mar 10, 2026
- Mar 5, 2026
- Mar 4, 2026
Frequently asked questions
What is Pulmonx's stock price?
Pulmonx (LUNG) closed at $714.91 on Oct 9, 2026, up 0.19% from the previous close of $713.54.
What is Pulmonx's market cap?
Pulmonx's market cap is $30.70B, based on a share price of $714.91 and 42.9M shares outstanding as of Jun 30, 2026.
How much revenue does Pulmonx make?
Pulmonx reported revenue of $90.50M for fiscal 2025, up 8.01% from fiscal 2024.
Does Pulmonx pay a dividend?
Pulmonx's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Pulmonx Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures